Notal Vision Secures $25 Million in Funding Round for ForeseeHome and Pipeline Technologies

By
More Images
MANASSAS, Va.—Notal Vision Inc., a privately held ophthalmic diagnostic services company focused on advancing eyecare with precision medicine, said this week that Ganot Capital is extending a recent funding round to $25 million. The continued investment will enable Notal Vision to support the commercial growth of the company’s current service, ForeseeHome AMD Monitoring Program, as well as further research and development efforts for pipeline technologies, according to the announcement. “Pursuing additional funding has allowed us to expand our ForeseeHome field-based sales team,” chief executive officer Kester Nahen said in the announcement. “We have a proven model that includes low-cost medical devices, an effective artificial intelligence (AI)-driven decision support solution, and a dependable clinical patient engagement platform. With the additional investment, we believe we will be able to prove that partnering with accounts as an extension of their practice will drive deeper adoption of our home diagnostic services.”

The company said its funding will allow it to continue development of the Home OCT platform, which received FDA “breakthrough device status” at the end of 2018. Notal Vision also said the effort to establish reimbursement is “well under way,” and that the home-based OCT will help to address the high unmet monitoring need for physicians and their patients alongside anti-VEGF therapy.

“Notal Vision is uniquely positioned to continue to lead the ophthalmic home diagnostic services market,” chairman Guy Kastav said in the announcement. “Ganot Capital is an investment company dedicated to improving quality of life for senior citizens.”